Search Medical Condition
Please enter condition
Please choose location

Ho Chi Minh City, Vietnam Clinical Trials

A listing of Ho Chi Minh City, Vietnam clinical trials actively recruiting patients volunteers.

RESULTS

Found (14) clinical trials

Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Phase III multicenter, international, open-label, randomized trial evaluating non-inferiority of raltegravir at dose of 400mg BID compared to efavirenz 600mg QD, both in association with tenofovir disoproxil fumarate and lamivudine in ART-naïve HIV-1 infected patients with active TB disease receiving a rifampin-based TB treatment initiated <8 weeks before inclusion. Patients ...

Phase

0.0 miles

Learn More »

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

The purpose of this study is to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab. Purpose of the study is also ...

Phase

0.0 miles

Learn More »

Global Non-interventional Heart Failure Disease Registry

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for ...

Phase N/A

0.0 miles

Learn More »

A Study of Durvalumab Versus Standard of Care in Advanced Non Small-Cell Lung Cancer

Patients will be randomized in a 1:1 ratio to 2 treatment arms (durvalumab or SOC therapy). The Co-primary objectives of this study are to assess the efficacy of durvalumab compared to SoC in terms of PFS (Progression Free Survival) and OS (Overall Survival) in patients with NSCLC

Phase

0.0 miles

Learn More »

Study to Patients With Stable COPD to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate (DUAKLIR)

This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).

Phase

0.0 miles

Learn More »

A Study of ELIGARD in Hormone-dependent Prostate Cancer Patients

The objective of this study is to evaluate the safety, efficacy, and impact on quality of life (QoL) of ELIGARD® in hormone-dependent prostate cancer patients in Asia.

Phase

0.0 miles

Learn More »

Clinical Effects of a Formula With Modified Protein Levels and Fat Blend in Preterm Infants

When an infant is born prematurely, the supply of nutrients supporting normal growth and development is interrupted. There is less time to accrue adequate nutrient stores and foetal tissue. The nutritional goal for the preterm infant is to have satisfactory functional development and catch up on growth to match the ...

Phase N/A

0.0 miles

Learn More »

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Na ve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 2 4 5 or 6 Infection and Compensated Cirrhosis

A Phase 3b, single arm, open-label, multicenter study to evaluate the safety and to demonstrate the non-inferiority of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with the glecaprevir (GLE)/pibrentasvir (PIB) combination regimen to the historical SVR12 rate of 12 weeks of treatment ...

Phase

0.0 miles

Learn More »

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir (ABT-493)/pibrentasvir (ABT-530) for an 8- or 12-week treatment duration in participants with chronic Hepatitis C Virus (HCV) genotype (GT) 5 or 6 infection, with or without compensated cirrhosis, who are either HCV treatment-naïve or treatment experienced ...

Phase

0.0 miles

Learn More »

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »